Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma

Basic Information

Funding Cycle : 2022-2023
Name : Sara Taranto
Type of Award : Career Development Award
Home Institution : University of Brescia, Italy
Host Institution : Ohio State University


Multiple myeloma (MM) is a rare neoplastic disorder characterized by uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM). In the last decade, the therapeutic approaches to treat MM patients have been improved. Nevertheless, the urgent need to identify new therapeutic targets remains to develop more effective strategies against this uncurable disease. The principal aim of my research project was investigate the biology and the interactome of the trascription factor CREB1 (Cyclic AMP-responsive element-binding protein 1) in high-risk multiple myeloma models to provide insights for novel therapeutic opportunities in MM. The definition of genes regulated by CREB1 signaling can help to identify tailored therapeutic strategies for patients with t(4;14) or high CD56 expression. Moreover, the inhibition of CREB1 signaling can promote cell death and improve anti-MM activity. My research year in Dr. Cottini Lab was sustained by IMS award that gave me the opportunity to improve my knowledges in the field of multiple myeloma in an international work environment.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events